Monte Rosa Therapeutic (GLUE) Q3 2026 earnings summary

Executive summary

• Q3 collaboration revenue was $54.4M, primarily from a $50M Novartis milestone; net income was $3.1M versus a $27.1M loss YoY.

• Nine-month revenue was $67.5M and net loss was $84.8M; R&D investment continued to advance clinical and discovery programs.

• Cash, cash equivalents, restricted cash and marketable securities totaled $582.6M at September 30, 2026; management expects runway into 2029.

Financial highlights

• Q3 revenue rose to $54.4M from $12.8M YoY, primarily reflecting the $50M Novartis Sjögren’s disease milestone.

• Q3 R&D was $45.4M versus $36.7M, and G&A was $10.9M versus $9.1M; operating expenses increased to $56.3M from $45.7M.

• Q3 net income was $3.1M versus a $27.1M net loss in Q3 2025.

• Nine-month revenue declined to $67.5M from $120.9M, reflecting the prior-year Novartis upfront payment; net loss was $84.8M versus net income of $7.5M.

• Nine-month R&D rose to $137.4M from $99.5M and G&A to $31.3M from $25.9M.

Outlook and guidance

• GEMINI-1 Phase 2 in gout is expected to start in Q4 2026, with initial data in H2 2027; GFORCE-2 in stable CAD and GALAXY-1 in hidradenitis suppurativa are expected to start in H1 2027.

• MRT-2359 updates are expected by year-end 2026 for the enzalutamide expansion arm and in 2027 for MODEFIRe-1; CDK2- and CCNE1-directed MGD IND submissions are expected in 2027.

• Cash, cash equivalents, restricted cash and marketable securities are expected to support operations into 2029.

• R&D, G&A and capital expenditures are expected to increase as clinical trials, manufacturing and pipeline development advance.